Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — In the coming weeks, Democrats will embark on an ambitious effort to change the way seniors, and maybe millions of other people, pay for prescription drugs in the United States — if they can get by the drug industry first.

The effort’s success depends on the calculations and sausage-making chops of a number of lawmakers and White House officials, as well as the effectiveness of industry lobbyists working to stop them. The path to the major drug pricing reform Democrats are eyeing will be a slog, if it happens at all.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment